Papers
Ozyerli-Goknar E, Kala EY, Aksu AC, Bulut I, Cingöz A, Niuzamuddin S, Biniossek M, Seker-Polat F, Morova T, Aztekin C, Kung S, Syed H, Tuncbag N, Gonen M, Philpott M, Cribbs A, Acilan C, Lack NA, Onder TT, Timmers HTM, Bagci-Onder T. “Epigenetic-focused CRISPR/Cas9 screen identifies ASH2L as a regulator of glioblastoma cell survival”. bioRxiv 2022.08.17.504245. doi: https://doi.org/10.1101/2022.08.17.504245 Download
Yedier-Bayram O, Gökbayrak B, Aksu AC, Cavga AD, Kayabolen A, Kala EY, Karabiyik G, Cingöz A., Günsay R, Morova T, Uyulur F, Lack, NA, Onder TT and Bagci-Onder T. "EPIKOL, a chromatin-focused CRISPR/Cas9 library identifies cancer-specific epigenetic vulnerabilities". Cell Death Dis 13, 710 (2022)Download
Kayabolen A, Akcan U, Özturan D, Ulbegi-Polat H, Sahin GN, Pinarbasi-Degirmenci N, Bayraktar C, Soyler G, Sarayloo E, Nurtop E, Ozer B, Guney-Esken G, Barlas T, Yildirim IS, Dogan O, Karahuseyinoglu S, Lack NA, Kaya M, Albayrak C, Can F, Solaroglu I, Bagci-Onder T. “Protein Scaffold-Based Multimerization of Soluble ACE2 Efficiently Blocks SARS-CoV-2 Infection In Vitro and In Vivo". Adv Sci, 2022. Download
Bagci-Onder T, Kutuk O, Chonghaile TN, Knippschild U. “Editorial: Cell Death and Targeted Cancer Therapies". Front Cell Dev Biol, 2022. Download
Pinarbasi-Degirmenci N, Sur-Erdem I, Akcay V, Bolukbasi Y, Selek U, Solaroglu I, Bagci-Onder T. “Chronically Radiation-Exposed Survivor Glioblastoma Cells Display Poor Response to Chk1 Inhibition under Hypoxia". Int J Mol Sci, 2022. Download
Zhang Y, Donaher JL, Das S, Li X, Reinhardt F, Krall JA, Lambert AW, Thiru P, Keys HR, Khan M, Hofree M, Wilson MM, Yedier-Bayram O, Lack NA, Onder TT, Bagci-Onder T, Tyler M, Tirosh I, Regev A, Lees JA, Weinberg RA. “Genome-wide CRISPR screen identifies PRC2 and KMT2D-COMPASS as regulators of distinct EMT trajectories that contribute differentially to metastasis". Nat Cell Biol, 2022. Download
Seker-Polat F, Pinarbasi Degirmenci N, Solaroglu I, Bagci-Onder T. “Tumor Cell Infiltration into the Brain in Glioblastoma: From Mechanisms to Clinical Perspectives". Cancers, 2022. Download
Ustun M, Dabbagh SR, Ilci IS, Bagci-Onder T, Tasoglu S. “Glioma-on-a-Chip Models”. Micromachines (Basel), 2021. Download
Kayabolen A, Yilmaz E, Bagci-Onder T. “IDH Mutations in Glioma: Double-Edged Sword in Clinical Applications?”. Biomedicines, 2021. Download
Ozyerli-Goknar E, Bagci-Onder T. “Epigenetic Deregulation of Apoptosis in Cancers”. Cancers, 2021. Download
Ustun M, Dabbagh SR, Ilci IS, Bagci-Onder T, Tasoglu S. “Glioma-on-a-Chip Models”. Micromachines, 2021. Download
Cingöz A, Ozyerli-Goknar E, Morova T, Seker F, Selvan M, Gumus ZH, Bhere D, Shah K, Bagci-Onder T. “Generation of TRAIL-resistant cell line models reveals adoption of different mechanisms of acquired resistance and re-sensitization”. Oncogene, 2021. Download
Kayabolen A, Sahin GN, Seker F, Cingoz A, Isik B, Acar S, Solaroglu I, Wakimoto H, Cahill D, Cribss A, Oppermann U, Bagci-Onder T. “Combination of epigenetic enzyme inhibitors, GSKJ4 and Belinostat, reveals efficacy in IDH1 mutant gliomas”. bioRxiv, 2020.11.26.400234; Download
Senbabaoglu F, Aksu AC, Cingoz A, Seker F, Kahya Z, Solaroglu I, Bagci-Onder T. “Drug Repositioning Screen on a New Primary Cell Line Identifies Potent Therapeutics for Glioblastoma”. Front. Neurosci, 2020, Dec 17;14:578316.Download
Sur-Erdem I, Muslu K, Pinarbasi N, Altunbek M, Seker F, Cingoz A, Kahraman M, Culha M, Solaroglu I, Bagci-Onder T. “TRAIL conjugated silver nanoparticles sensitize glioblastoma cells to TRAIL by regulating CHK1 in the DNA repair pathway”. Neurol. Res. 2020. 42(12):1061-1069.Download
Saraç H, Morova T, Pires E, McCullagh J, Kaplan A, Cingöz A, Bagci-Onder T, Onder T, Kawamura A, Lack N. “Systematic characterization of chromatin modifying enzymes identifies KDM3B as a critical regulator in castration resistant prostate cancer”. Oncogene, Dec 10, 2019. Download
Ozyerli-Goknar E, Sur-Erdem I, Seker F, Cingöz A, Kayabolen A, Kahya Z, Uyulur F, Gezen M, Erman B, Gonen M, Oppermann U, Bagci-Onder T. “The fungal metabolite chaetocin is a sensitizer for pro-apoptotic therapies in glioblastoma”. Cell Death Dis., 10 (12), 894. Nov 26, 2019. doi: https://doi.org/10.1038/s41419-019-2107-y Download
Seker F, Cingoz A, Sur-Erdem I, Ergüder N, Erkent A, Uyulur F, Selvan M, Gümüş ZH, Gönen M, Bayraktar H, Wakimoto H, Bagci-Onder T. “Identification of SERPINE1 as a regulator of glioblastoma cell dispersal with transcriptome profiling”. Cancers, Oct. 2019., 11(11), 1651.
doi: https://doi.org/10.3390/cancers11111651 Download
Ezgi Kaya-Aksoy, Ahmet Cingoz, Filiz Senbabaoglu, Fidan Seker, Ilknur Sur-Erdem, Alisan Kayabolen, Tolga Lokumcu, Gizem Nur Sahin, Sercin Karahuseyinoglu, Tugba Bagci-Onder. "The pro-apoptotic Bcl-2 family member Harakiri (HRK) induces cell death in glioblastoma multiforme". Cell Death Discovery ( 2019) 5:64. https://doi.org/10.1038/s41420-019-0144-z Download
Bhere D, Khajuria RK, Hendriks WT, Bandyopadhyay A, Bagci-Onder T, Shah K.,"Stem Cells Engineered During Different Stages of Reprogramming Reveal Varying Therapeutic Efficacies". Stem Cells. 2018 Jun;36(6):932-942. doi: 10.1002/stem.2805.
Erkoc P, Seker F, Bagci-Onder T*, Kizilel S.*, "Gelatin Methacryloyl Hydrogels in the Absence of a Crosslinker as 3D Glioblastoma Multiforme (GBM)-Mimetic Microenvironment". Macromolecular Bioscience, Dec 2017. doi: 10.1002/mabi.201700369.
Kurt IC, Sur I, Kaya E, Cingoz A, Kazancioglu S, Kahya Z, Toparlak OD, Senbabaoglu F, Kaya Z, Ozyerli E, Karahüseyinoglu S, Lack NA, Gümüs ZH, Onder TT, Bagci-Onder T., “KDM2B, an H3K36-specific demethylase, regulates apoptotic response of GBM cells to TRAIL”. Cell Death Dis. 2017 Jun 29;8(6):e2897. DOI: 10.1038/cddis.2017.288.
Adiguzel Z, Ozalp-Yaman S, Celik G, Salem S, Bagci-Onder T, Senbabaoglu F, Cetin Y, Acilan C. "A platinum-blue complex exerts its cytotoxic activity via DNA damage and induces apoptosis in cancer cells". Chem Biol Drug Des. 2017 Jan 12. doi: 10.1111/cbdd.12940.
Erkoc P, Cingoz A, Bagci-Onder T, Kizilel S. "Quinacrine Mediated Sensitization of Glioblastoma (GBM) cells to TRAIL through MMP-sensitive PEG Hydrogel Carriers". Macromolecular Bioscience, 2016 Oct 20. doi: 10.1002/mabi.201600267.
Senbabaoglu F, Cingoz A, Kaya E, Kazancioglu S, Lack N, Acilan C, Bagci-Onder T. "Identification of Mitoxantrone as a TRAIL-sensitizing agent for Glioblastoma Multiforme". Cancer Biology and Therapy, 17, pg: 546-557, 2016.
Uzer B, Toker SM, Cingoz A, Bagci-Onder T, Gerstein G, Maier HJ, Canadic D. “An exploration of plastic deformation dependence of cell viability and adhesion in metallic implant materials”. Journal of the Mechanical Behavior of Biomedical Materials, 60, pp.177–186, 2016.
Bagci-Onder T, Du W, Figueiredo JL, Martinez-Quintanilla J, Shah K. “Targeting metastatic cells withtherapeutic stem cells in an imageable breast to brain metastasis tumor model”. Brain, 2015 Jun;138(Pt 6):1710-21.
Bagci-Onder T. “Neural stem cells as therapeutic delivery vehicles for malignant brain tumors”. Stem Cells and Regenerative Medicine: Progress and Challenges. 2013, Published by Springer Science+Business Media. Pg: 253-277.
Bagci-Onder T. “Stem cell based combination therapies for cancer: Systemic delivery of a PI3K/mTOR inhibitor and stem cell mediated delivery of TRAIL in brain tumors”. Stem Cell Based Therapeutics for Cancer. 2013, Published by Wiley Blackwell. Pg: 219-234.
Bagci-Onder T, Agarwal AS, Flusberg D, Wanningen S, Sorger P, Shah K. “Real-time imaging of the dynamics of death receptors and combinatorial therapies that overcome TRAIL resistance in tumors”. 2013 Jun 6;32(23):2818- 27. doi: 10.1038/onc.2012.304. Epub 2012 Jul 23.
Bagci-Onder T, Wakimoto H, Anderegg MC, Cameron C, Shah K. “A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem-cell delivered TRAIL in experimental glioma models”. Cancer Research. 2011 Jan 1;71(1):154-63.
Van de Water JA, Bagci-Onder T, Agarwal AS, Wakimoto H, Roovers RC, Zhu Y, Kasmieh R, Bhere D, Van Bergen En Henegouwen PM, Shah K. “Therapeutic stem cells expressing different variants of EGFR-specific nanobodies have anti-tumor effects”. Proc Natl Acad USA. 2012 Oct 9;109(41):16642-7.
Wanningen S, Nesterenko I, Bagci-Onder T, Anderegg MC, Shah K. “Evaluating the effect of therapeutic stem cells on TRAIL resistant and sensitive medulloblastomas”. PLOS One. 2012;7(11):e49219. doi: 10.1371/journal.pone.0049219
Cain JW, Hauptschein R, Bagci T, Stewart J, Sahagian G, Jay DG. “Identification of CD44 as a novel surface biomarker for drug resistance by surface proteome signature technology”. Mol Cancer Res. 2011 May;9(5):637- 47.
Bagci T, Wu JK, Pfannl R, Ilac LL, Jay DG. “Autocrine Sema3A signaling promotes glioblastoma dispersal”. Oncogene 2009 Oct 8;28(40):3537-50.
Selected Posters
Cingoz A, Gümüş ZH, Gonen M, Bagci-Onder T. “Examining GBM cell lines with varying apoptotic responses identifies IGFBP-2 as a novel mediator of TRAIL resistance ”. Translational Research in Cancer Cell Metabolism Conference, Bilbao, Spain, 2016.
Kaya E, Cingoz A, Senbabaoglu F, Bagci-Onder T. "Induced Expression Of Harakiri (HRK), A Pro-Apoptotic Bcl-2 Family Member, Leads To Cell Death In Glioblastoma Multiforme Cells" EACR A Matter of Life or Death: Mechanisms and Relevance of Cell Death for Cancer Biology and Treatment Amsterdam, Netherlands, 2016.
Cingoz A, Gümüş ZH, Bagci-Onder T. “IGFBP2 Is A Novel Molecular Determinant In TRAIL-Resistant Subpopulations Of GBM Cell Lines”. Social for NeuroOncology (SNO) 2015 Annual Meeting, San Antonio, TX, 2016.
Kurt IC, Kahya Z, Kazancioglu S, Cingoz A, Lack N, Gumus ZH, Onder TT, Bagci-Onder T. “The Function Of Chromatin-Modifying Enzymes In GBM Cell Apoptosis”. Social for NeuroOncology (SNO) 2015 Annual Meeting, San Antonio, TX, 2016.
Senbabaoglu F, Cingoz A, Kaya E, Kazancioglu S, Lack AN, Acilan C, Bagci-Onder T. "Screen Among 1200 FDA-Approved Drug Library Reveals Mitoxantrone As A TRAIL-Sensitizing Agent For Glioblastoma Multiforme". AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA, 2015.
Cingoz A, Gümüş ZH, Bagci-Onder T. “Understanding Tumor Heterogeneity In GBM Cell Lines With Differential TRAIL Sensitivity/Resistance”. International Cell Death Society (ICDS) Meeting, Prague, Czech Republic, 2015.
Kurt IC, Kahya Z, Cingoz A, Kaya E, Lack N, Gumus ZH, Onder T, Bagci-Onder T. “KDM2B, an H3K36-Specific Demethylase Regulates Apoptotic Response of GBM Cells to TRAIL”. International Cell Death Society (ICDS) Meeting, Prague, Czech Republic, 2015.
Erkoc P, Cingoz A, Mohammadi M, Bagci-Onder T, Kizilel S., “MMP-sensitive PEG Hydrogel Microspheres for Targeted Delivery of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) into Glioblastoma (GBM) Cells.” Fourth International Symposium Frontiers in Polymer Science, Riva del Garda, Italy, 2015.
Cingoz A, Senbabaoglu F, Bagci-Onder T. “Isolation of Isogenic GBM Cell Lines with Differential TRAIL Sensitivity/Resistance”. International Cell Death Society (ICDS) Meeting, Stellenbosch, South Africa, 2014.
Kurt IC, Kahya Z, Toparlak D, Lack N, Onder T, Bagci-Onder T. “Interrogating the function of chromatin modifying enzymes in TRAIL response of GBMs”. International Cell Death Society (ICDS) Meeting, Cape Town, South Africa, 2014.
Senbabaoglu F, Bildik G, Bagci-Onder T, Oktem O, Solaroglu I. "GnRH Signalling: New Insights into the Pathogenesis of High Grade Gliomas". International Cell Death Society (ICDS) Meeting, Cape Town, South Africa, 2014.